Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BMS-955176 TQT study in healthy subjects
NCT02576119Phase 1Terminated
- Sponsor
- ViiV Healthcare
- Start
- Oct 2015
- Primary completion
- Feb 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of BMS-955176 in human immunodeficiency virus infection (HIV) (2 arms), sponsored by ViiV Healthcare. Primary endpoints: Reported adverse events, Vital sign measurements and 3 more. Started Oct 2015; status: terminated.
02
Drugs
BMS-955176
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on NCT02576119.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02576119.